A Rutgers researcher is developing a new drug that might help in battling against the type 2 diabetes, which would attack the root cause of the disease.
New research shows promising evidence that a modified form of a different drug, niclosamide, now used to eliminate intestinal parasites, might hold the key to battling the disease at its source.
Victor Shengkan Jin said it was important to find a suitable medication to correct the cause of the disease as quickly as possible because the only way now known to "cure" the condition involves major gastric bypass surgery.
The modified medication, whose full name is niclosamide ethanolamine salt (NEN), burned the excess fat in liver cells through a process known as mitochondrial uncoupling. Mitochondria are the microscopic energy source for each cell in the body, and ordinarily, like a well-tuned car engine, they burn fuels including fats and sugars in modest quantities to keep the cells functioning.
Jin also mentioned that it was significant that the drug he used was a modified form of a medication that the FDA already approved for human use, so it was a deliberate choice.
.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
